Ovarian cancer (OC) is the most lethal gynecological neoplasm
in the world. From the histological point of view, OC
is subdivided into type I and II [1]. Type I includes distinct
tumor subtypes, i.e. low-grade serous carcinoma (LGSC),
endometrioid carcinoma, clear cell carcinoma and mucinous
carcinoma. Type II comprises high-grade serous cancer
(HGSC), malignant mixed Mullerian tumors and high-grade
endometroid ovarian carcinomas. Prognosis for type II is
worse than for type I. For all OC cases, the combination of
chemotherapy with surgery results in a five-year survival
rate of only 45%; survival rate is further reduced to 25%
for the very advanced forms. The limited survival descends
from the fact that in the initial phases OC does not give
a specific symptomatology, thus about 70% of the OC is
diagnosed in an advanced phase when the efficacy of therapeutic
options is modest. Moreover, in cases of recurrence,
OC demonstrates a high resistance to chemotherapy. Thus,
the identification of novel therapeutic strategies/molecular
targets both for firstly diagnosed and for recurring OC forms
is utmost urgent. Here, we focus on the description of the
E2 promoter binding factor 1 (E2F1), a transcription factor
relevant for the control of cell proliferation both in normal
and tumor cells like OC cell
